Acesion Pharma is a Danish biotech company founded in 2011. We are aiming to develop more efficacious and safer drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The scientific foundation of Acesion Pharma is the novel concept of treating AF by inhibiting the so-called SK channels. These are ion channels present in the heart where they are relevant for regulating the cardiac rhythm. Blocking this ion channel with a selective drug molecule constitutes a novel and promising target for developing improved treatment of AF.
Location: Denmark, Capital Region of Denmark, Copenhagen
Employees: 11-50
Total raised: $47.73M
Founded date: 2011
Investors 1
| Date | Name | Website |
| 26.10.2023 | Alpha Wave... | alphawaveg... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.09.2023 | Series B | $47.73M | - |
Mentions in press and media 2
| Date | Title | Description |
| 26.09.2023 | Acesion Pharma Raises €45M in Series B Financing | Acesion Pharma, a Copenhagen, Denmark-based biotech company pioneering first-in-class novel therapies for atrial fibrillation (‘AF’), closed a €45M Series B financing round. The financing was co-led by Canaan and Alpha Wave with participati... |
| 02.11.2016 | CRISPR upstart Casebia picks Sanofi vet Burns as new CEO; On the heels of a trial debacle, Opexa sheds staffers | Jim Burns, who had headed Sanofi’s R&D ops in Boston, is jumping ship to take the helm of Casebia Therapeutics, the $335 million gene editing JV created by Bayer and CRISPR Therapeutics $CRSP. Casebia recently inked a ... |